Michel Detheux
Gründer bei ITEOS THERAPEUTICS, INC.
Vermögen: 596 388 $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Michel Detheux
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 21 | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.
14
| Subsidiary | Pharmaceuticals: Major | 14 |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies.
4
| Holding Company | Biotechnology | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Michel Detheux
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor Private Equity Investor Private Equity Investor | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member Chairman | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member | |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chief Executive Officer | |
| Université Libre de Bruxelles | College/University | Undergraduate Degree Graduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Chairman | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Founder | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Banks/Brokers | Analyst-Equity Corporate Officer/Principal | |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman Director/Board Member | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Private Equity Investor | |
| University College London | College/University | Doctorate Degree Doctorate Degree | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Graduate Degree | |
Medlumics SL
 Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
Ludwig Institute for Cancer Research Ltd.
 Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Medical/Nursing Services | Corporate Officer/Principal Director/Board Member | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Founder Private Equity Investor | |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
| The University of Southampton | College/University | Doctorate Degree | |
Epics Therapeutics SA
 Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Corporate Officer/Principal | |
| The University of Wales | College/University | Doctorate Degree | |
| University of Pavia | College/University | Undergraduate Degree | |
Iteos Belgium SA
 Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Pharmaceuticals: Major | Founder | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Director/Board Member | |
| Julius-Maximilians-Universität Würzburg | College/University | Graduate Degree | |
| AstraZeneca Diagnostics | Corporate Officer/Principal | ||
Rekindle Therapeutics, Inc.
 Rekindle Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rekindle Therapeutics, Inc. operates as an biotechnology company. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Executive Officer | |
Tilos Therapeutics, Inc.
 Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Chief Executive Officer | |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
| Queen’S University Belfast | College/University | Undergraduate Degree | |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
| AELIS FARMA | Biotechnology | Director/Board Member | |
Mazars Group
 Mazars Group Miscellaneous Commercial ServicesCommercial Services Mazars Group provides audit, accountancy, tax, legal, and advisory services. Its services include financial reporting audit and advisory, consulting, financial advisory, outsourcing and accounting, actuarial, and international desks services. The company was founded by Robert Mazars in 1940 and is headquartered in Montr?al, Canada. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor |
Statistik
International
| Vereinigte Staaten | 26 |
| Vereinigtes Königreich | 7 |
| Belgien | 6 |
| Spanien | 5 |
| Frankreich | 5 |
Sektoral
| Health Technology | 29 |
| Consumer Services | 10 |
| Finance | 7 |
| Commercial Services | 6 |
| Health Services | 2 |
Operativ
| Director/Board Member | 209 |
| Corporate Officer/Principal | 69 |
| Independent Dir/Board Member | 54 |
| Private Equity Investor | 22 |
| Undergraduate Degree | 22 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| José Antonio Mesa Cejudo | 20 |
| Aaron Davis | 19 |
| Pamela Klein | 19 |
| Ann Rhoads | 19 |
| Matt Roden | 18 |
| Joël Jean-Mairet | 17 |
| Derek DiRocco | 17 |
| David Hallal | 15 |
| Tony Ho | 15 |
| Alexandra Tolia | 15 |
| Philippe M. R. Guinot | 13 |
| Jill DeSimone | 12 |
| Detlev Biniszkiewicz | 12 |
| Robert Iannone | 11 |
- Börse
- Insiders
- Michel Detheux
- Unternehmensverbindungen
